GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+ T-independent CTL responses

Vaccine

Volumn 29, Issue 19, 2011, Pages 3538-3547

  Nanjundappa, Roopa Hebbandi ^a,b   Wang, Rong ^a,b   Xie, Yufeng ^a,b   Umeshappa, Channakeshava Sokke ^a,b   Chibbar, Rajni ^b   Wei, Yangdou ^b   Liu, Qiang ^c   Xiang, Jim ^a,b  

^a SASKATCHEWAN CANCER AGENCY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

CD8+ CTL; Exosome; Gp120; T cell vaccine

Indexed keywords

CONCANAVALIN A; DENDRITIC CELL GLYCOPROTEIN GP 120; DENDRITIC CELL OVALBUMIN; DENDRITIC CELL VACCINE; EXOSOME GLYCOPROTEIN GP 120; EXOSOME OVALBUMIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120 TEXO VACCINE; HIV 1 GLYCOPROTEIN GP 120; OVALBUMIN; PLASMID CDNA GP120; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXOSOME; EXPRESSION VECTOR; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; EXOSOMES; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INTERCELLULAR ADHESION MOLECULE-1; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN;

EID: 79955010722     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.095     Document Type: Article

References (64)

1. Kim D.K., Tahara-Hanaoka S., Shinohara N., Nakauchi H. A human mutant CD4 molecule resistant to HIV-1 binding restores helper T-lymphocyte functions in murine CD4-deficient mice. Exp Mol Med 2007, 39(February (1)):1-7.
2. Chougnet C., Gessani S. Role of gp120 in dendritic cell dysfunction in HIV infection. J Leukoc Biol 2006, 80(November (5)):994-1000.
3. Aiuti F., Mezzaroma I. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006, 8(April-June (2)):88-97.
4. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277(July (5322)):112-116.
5. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278(November (5342)):1447-1450.
6. Autran B., Hadida F., Haas G. Evolution and plasticity of CTL responses against HIV. Curr Opin Immunol 1996, 8(August (4)):546-553.
7. Ogg G.S., Jin X., Bonhoeffer S., Moss P., Nowak M.A., Monard S., et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999, 73(January (1)):797-800.
8. Ramratnam B., Mittler J.E., Zhang L., Boden D., Hurley A., Fang F., et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000, 6(January (1)):82-85.
9. Coiras M., Lopez-Huertas M.R., Perez-Olmeda M., Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009, 7(November (11)):798-812.
10. Levy Y., Durier C., Lascaux A.S., Meiffredy V., Gahery-Segard H., Goujard C., et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006, 20(February (3)):405-413.
11. Autran B., Carcelain G., Combadiere B., Debre P. Therapeutic vaccines for chronic infections. Science 2004, 305(July (5681)):205-208.
12. Humbert M., Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev 2006, 8(April-June (2)):51-59.
13. Graham B.S., Mascola J.R. Lessons from failure - preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 2005, 191(March (5)):647-649.
14. Cohen J. AIDS research, promising AIDS vaccine's failure leaves field reeling. Science 2007, 318(October (5847)):28-29.
15. Kawada M., Tsukamoto T., Yamamoto H., Takeda A., Igarashi H., Watkins D.I., et al. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 2007, 81(May (10)):5202-5211.
16. Seaman M.S., Santra S., Newberg M.H., Philippon V., Manson K., Xu L., et al. Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. J Virol 2005, 79(April (8)):4580-4588.
17. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(June (12)):4781-4789.
18. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006, 6(December (12)):930-939.
19. Titti F., Cafaro A., Ferrantelli F., Tripiciano A., Moretti S., Caputo A., et al. Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs 2007, 12(March (1)):23-48.
20. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(March (6673)):245-252.
21. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5(April (4)):296-306.
22. Huang X.L., Fan Z., Borowski L., Rinaldo C.R. Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity. J Leukoc Biol 2008, 83(June (6)):1530-1540.
23. Van Gulck E.R., Vanham G., Heyndrickx L., Coppens S., Vereecken K., Atkinson D., et al. Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. J Virol 2008, 82(April (7)):3561-3573.
24. Lapenta C., Santini S.M., Logozzi M., Spada M., Andreotti M., Di Pucchio T., et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 2003, 198(July (2)):361-367.
25. Yoshida A., Tanaka R., Murakami T., Takahashi Y., Koyanagi Y., Nakamura M., et al. Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-cell origin. J Virol 2003, 77(August (16)):8719-8728.
26. Villamide-Herrera L., Ignatius R., Eller M.A., Wilkinson K., Griffin C., Mehlhop E., et al. Macaque dendritic cells infected with SIV-recombinant canarypox ex vivo induce SIV-specific immune responses in vivo. AIDS Res Hum Retroviruses 2004, 20(August (8)):871-884.
27. Carbonneil C., Aouba A., Burgard M., Cardinaud S., Rouzioux C., Langlade-Demoyen P., et al. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8T cells. AIDS 2003, 17(August (12)):1731-1740.
28. Larsson M., Wilkens D.T., Fonteneau J.F., Beadle T.J., Merritt M.J., Kost R.G., et al. Amplification of low-frequency antiviral CD8T cell responses using autologous dendritic cells. AIDS 2002, 16(January (2)):171-180.
29. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10(December (12)):1359-1365.
30. Garcia F., Lejeune M., Climent N., Gil C., Alcami J., Morente V., et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005, 191(May (10)):1680-1685.
31. Ide F., Nakamura T., Tomizawa M., Kawana-Tachikawa A., Odawara T., Hosoya N., et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006, 78(June (6)):711-718.
32. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4(May (5)):594-600.
33. Hao S., Yuan J., Xiang J. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. J Leukoc Biol 2007, 82(October (4)):829-838.
34. Xiang J., Huang H., Liu Y. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 2005, 174(June (12)):7497-7505.
35. Jung S., Unutmaz D., Wong P., Sano G., De los Santos K., Sparwasser T., et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 2002, 17(August (2)):211-220.
36. Prlic M., Hernandez-Hoyos G., Bevan M.J. Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. J Exp Med 2006, 203(September (9)):2135-2143.
37. Wiedemann A., Depoil D., Faroudi M., Valitutti S. Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc Natl Acad Sci U S A 2006, 103(July (29)):10985-10990.
38. Liu Y., Huang H., Chen Z., Zong L., Xiang J. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. J Gene Med 2003, 5(August (8)):668-680.
39. Xie Y., Bai O., Zhang H., Yuan J., Zong S., Chibbar R., et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumor immunity than exosomes released from heat-shocked tumor cells expressing cytoplasmic HSP70. J Cell Mol Med July 2009.
40. Xia D., Hao S., Xiang J. CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J Immunol 2006, 177(September (5)):2976-2984.
41. Bondanza A., Valtolina V., Magnani Z., Ponzoni M., Fleischhauer K., Bonyhadi M., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006, 107(March (5)):1828-1836.
42. Shi M., Hao S., Chan T., Xiang J. CD4(+) T cells stimulate memory CD8(+) T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. J Leukoc Biol 2006, 80(December (6)):1354-1363.
43. Thery C., Boussac M., Veron P., Ricciardi-Castagnoli P., Raposo G., Garin J., et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001, 166(June (12)):7309-7318.
44. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002, 169(December (11)):6376-6385.
45. Shedlock D.J., Whitmire J.K., Tan J., MacDonald A.S., Ahmed R., Shen H. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J Immunol 2003, 170(February (4)):2053-2063.
46. Harari A., Petitpierre S., Vallelian F., Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004, 103(February (3)):966-972.
47. Patel D.M., Dudek R.W., Mannie M.D. Intercellular exchange of class II MHC complexes: ultrastructural localization and functional presentation of adsorbed I-A/peptide complexes. Cell Immunol 2001, 214(November (1)):21-34.
48. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9(August (8)):581-593.
49. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003, 198(December (12)):1909-1922.
50. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(April (4)):247-258.
51. Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008, 222(April):129-144.
52. Shankar P., Russo M., Harnisch B., Patterson M., Skolnik P., Lieberman J. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 2000, 96(November (9)):3094-3101.
53. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002, 169(September (6)):3447-3458.
54. Ramsburg E.A., Publicover J.M., Coppock D., Rose J.K. Requirement for CD4T cell help in maintenance of memory CD8T cell responses is epitope dependent. J Immunol 2007, 178(May (10)):6350-6358.
55. Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004, 10(August (8)):806-810.
56. Donaghy H., Pozniak A., Gazzard B., Qazi N., Gilmour J., Gotch F., et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001, 98(October (8)):2574-2576.
57. Pacanowski J., Kahi S., Baillet M., Lebon P., Deveau C., Goujard C., et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001, 98(November (10)):3016-3021.
58. Hladik F., McElrath M.J. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008, 8(June (6)):447-457.
59. Kishimoto C., Takada H., Hiraoka Y., Shinohara H., Kitazawa M. Protection against murine coxsackievirus B3 myocarditis by T cell vaccination. J Mol Cell Cardiol 2000, 32(December (12)):2269-2277.
60. Hong J., Zang Y.C., Nie H., Zhang J.Z. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103(March (13)):5024-5029.
61. Li Pira G., Ivaldi F., Bottone L., Koopman G., Manca F. Helper function of cytolytic lymphocytes: switching roles in the immune response. Eur J Immunol 2007, 37(January (1)):66-77.
62. Shanker A., Verdeil G., Buferne M., Inderberg-Suso E.M., Puthier D., Joly F., et al. CD8T cell help for innate antitumor immunity. J Immunol 2007, 179(November (10)):6651-6662.
63. Grassi F., Hosmalin A., McIlroy D., Calvez V., Debre P., Autran B. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS 1999, 13(May (7)):759-766.
64. Ye Z., Chen Z., Sami A., El-Gayed A., Xiang J. Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity. Cancer Biother Radiopharm 2006, 21(December (6)):613-622.